In conclusion, among individuals with diabetes, identifying patients with MetS may further increase the use of statin therapy for primary CVD prevention.
Introduction
Metabolic syndrome refers to a clustering of several cardiovascular disease (CVD) risk factors 1 within certain individuals; it affects approximately 25% of adults in the UK 2 and the US. 3 Many studies have shown that affected patients are at increased risk of developing cardiovascular diseases. 4, 5 The Expert Panel of the US National Cholesterol Education Program (NCEP) highlighted the management of metabolic syndrome as essential in the battle to reduce CVD mortality. 6 This was reflected by recent guidelines for primary CVD prevention, which advocate the identification of metabolic syndrome among patients with or without diabetes in routine clinical practice to help risk-stratify patients who might be suitable for intensive lipid-lowering therapy. 7, 8 Since clinical trials have yet to substantiate an independent benefit for therapy that raises levels of high-density lipoprotein cholesterol (HDL-C) in reducing CVD events, statin treatment to lower levels of low-density lipoprotein cholesterol (LDL-C) remains the first-line therapeutic intervention for CVD prevention in patients with metabolic syndrome. A retrospective analysis of data from the Treating to New Targets study (a comparison of 10 mg and 80 mg atorvastatin) suggested that patients with diabetes and/or the metabolic syndrome would benefit most from intensive statin therapy. 9 More recently however, the clinical usefulness of identifying metabolic syndrome, particularly among patients with diabetes, has been debated. [10] [11] [12] Central to this debate is the pertinent question of whether knowledge of a patient's metabolic syndrome status would provide additional clinically useful information to guide treatment with statins beyond current guidelines. In the UK, public health strategies for primary CVD prevention with statins in patients with diabetes have focused on three main treatment recommendations. The Joint British Societies' (JBS)-2 guidelines
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The clinical impact of identifying metabolic syndrome in patients with diabetes: a cross-sectional study recommend treating all patients with diabetes above the age of 40, 7 irrespective of baseline cholesterol levels. The National Institute for Health and Clinical Excellence (NICE) advocates the use of statins in diabetes patients with high risk for developing CVD, 8 while the General Medical Services (GMS) contract provides financial incentives to general practition-ers for treating patients with total cholesterol levels above 5.0 mmol/L. 13 Since the main aim of treatment recommendations is to identify patients for statin therapy, we aimed: (i) to determine whether identifying individuals with the metabolic syndrome among patients with diabetes without overt CVD would affect the decision to prescribe statin for primary CVD prevention, based on different public health guidelines; and (ii) to calculate sensitivity and positive predictive values of different strategies for detecting metabolic syndrome among patients with diabetes.
Methods
This was a cross-sectional cohort study derived from The Health Improvement Network (THIN), containing anonymous patient data sets from 304 general practices throughout England and Wales. THIN has been scrutinised at the practice and at the data set level: 14 its representativeness has been validated by comparing THIN data with those from various national data sources, including Department of Health-issued read codes for the Quality and Outcomes Framework (QOF), 2001 census figures and data from the Office for National Statistics (ONS); (www.statistics.gov.uk). Included in our study were diabetes patients aged between 30 and 74 years, who were not currently prescribed any lipid-lowering drug therapy and without known arterial disease. The age criteria were chosen on the basis that decisions to initiate statins below or above those age criteria would be based on individual risk basis rather than a public health perspective. We identified a total of 60,258 patients with diabetes and 11,005 patients fulfilled the inclusion criteria described above. Patients' biochemical and demographic profiles available on 31st December, 2005 were analysed. A national estimate was calculated using a multiplication factor of 32, derived from the ratio of the number of people with diabetes in England and Wales (1,922,051 at an estimated type 2 diabetes prevalence of 3.6%) with the total diabetes cohort obtained from the THIN data set. Metabolic syndrome was diagnosed based on the modified International Diabetes Federation (IDF BMI ) criteria. 15 A body mass index (BMI) cut-off of 25 kg/m 2 was used as this is equivalent to the IDF-defined waist circumference threshold of 94 cm and 80 cm for caucasian men and women, respectively, as calculated in a regression between BMI and waist in a large UK population. 16 By considering different primary CVD prevention strategies (JBS-2, CVD risk assessment and GMS contract), we calculated the number (and proportion) of patients who would not have been considered for statin therapy if their metabolic syndrome status were unknown. We calculated the sensitivity and positive predictive value of different strategies to ORIGINAL ARTICLE Normally distributed data were presented as means + standard deviation (SD), skewed data as the median (ranges) and categorical data as percentages. Student t-tests, chi-squared and regression analysis were used. As there is clustering (of patients within practices), the random effects logistic regression technique was used.
Results
The total prevalence of metabolic syndrome (MetS) in this cohort was 67.3%. Prevalence of MetS was similar for males and females and similar with different age cut-offs (ranging from 67.3% to 70.3%) (table 1). Table 2 shows the baseline characteristics of patients. MetS status did not affect glycosylated haemoglobin (HbA 1C ) levels. The LDL-C level was significantly higher for patients with MetS compared with patients without MetS in females, but not in males. All other CVD risk parameters were significantly less favourable for patients with MetS compared with patients without MetS. The proportion of patients with a 10-year CVD risk > 20% was significantly higher for patients with MetS compared with patients without MetS. By considering three different treatment strategies, those of the JBS-2 guidelines, CVD risk and GMS contract, among patients with MetS, we found that the proportions of patients with diabetes who would have not been eligible otherwise for primary CVD prevention strategies with statins were 8.4%, 29.6% and 41.9%, respectively. When extrapolated to the national estimate for this age group, these proportions translate to an additional 29,536, 104,288 and 147,328 patients, respectively, who would benefit from statin treatment on the basis of their MetS status. The JBS-2 treatment strategy was the most sensitive in including patients with MetS for primary CVD prevention with statin (87.5%), followed by the CVD risk strategy (57.3%) and the GMS contract recommendations (37.8%) (table 3).
Discussion
Despite the potential benefits of statin therapy, irrespective of estimated CVD risk or cholesterol levels, blanket use of statins may potentially expose people at lower risk to lifelong treatment, with attendant adverse effects and lack of compliance. Within a healthcare system that has finite financial resources, the use of risk assessment may be more effective to prevent CVD among patients with diabetes because higher-risk individuals are likely to gain the most in absolute terms. 17, 18 This study showed that among patients with diabetes without overt CVD, aged 30-74 years, knowledge of patients' MetS status would pick up a significant proportion of patients who would not have been eligible otherwise for statin therapy if various treatment guidelines were followed. Treating all diabetes patients above the age of 40 years (JBS-2 guidelines) was the most sensitive in detecting patients with MetS, followed by treating high-risk patients (NICE guideline) and treating patients with cholesterol > 5.0 mmol/L (GMS contract). Importantly, the recommendation to initiate statin therapy routinely for individuals above the age of 40 years is also recommended by the IDF. Our findings therefore add to the ongoing debate on the clinical utility of identifying patients with MetS within routine clinical practice for CVD prevention.
It has been argued that the presence of MetS in itself does not add to CVD prediction or affect the decision to treat its individual component risk factors. 10, 11 For example, no additional advantage was seen when some of the unique MetS factors were added to or substituted in the Framingham risk equation when determining an individual's CVD risk. 19 Furthermore, the criteria for MetS used an arbitrarily defined risk threshold rather than a linearly related risk gradient to detect individuals with a different degree of risk. However, a community-based cohort study with a longer follow-up period has shown that MetS (NCEP definition) was an independent risk factor for CVD even after adjustment for more established risk factors for CVD. 20 Similar results were obtained when MetS criteria were applied to newly diagnosed patients with type 2 diabetes. 21 Whilst we accept that individual CVD risk factors should be aggressively treated irrespective of the patient's MetS status, this argument needs to be balanced by the practicalities of various public health approaches to primary CVD prevention using application of treatment guidelines to a large number of patients. Our ORIGINAL ARTICLE 22 We do, however, agree that identifying MetS among diabetes patients with clinical CVD is currently unjustified. We also accept the limitations of using the MetS criteria per se to determine CVD risk and therefore advocate use of MetS criteria only in combination with other conventional CVD risk factors.
Some limitations of the study should be mentioned. The presence of diabetes was dependent on patients attending the general practitioner and would therefore not identify people with undiagnosed diabetes. The data set did not record waist circumference and hence a modified definition of the MetS was used, which is valid when applied to a large population, as previously adopted by Sattar et al. 2, 12 Moreover, a recent meta-analysis showed no heterogeneity when determining vascular risk irrespective of whether waist, waist-hip ratio or BMI was used as one of the criteria for MetS. 23 Information on diabetes duration, microalbuminuria status or type of diabetes was also unavailable. Again, this should not affect the outcome of this study because primary CVD prevention strategies in the UK do not distinguish between types of diabetes nor take diabetes duration into account, whereas the presence of microalbuminuria is an immediate indication for statins on the basis of secondary prevention. Although Framingham risk calculation is thought to underestimate the mean CVD risk of patients with diabetes, previous work has shown that such underestimation is only relevant when considering patients whose 10-year risk of coronary heart disease is > 20%. 24 Furthermore, the Framingham equation has been validated in the UK population. 25 When implementing a public health strategy for statin treatment in patients with diabetes, a cost-effective strategy is one that will give a high detection rate but that will also identify the patients who will benefit most. Given the high CVD event rate in patients with MetS, it is important to include affected patients in primary CVD prevention. Our findings suggest that identifying patients with MetS may be necessary even in patients with diabetes, particularly when treatment decisions are based on estimating CVD risk or an arbitrary cholesterol level.
